reported that berberine could alleviate HFD-induced inhibition of mitochondrial β-OX through SIRT3-mediated LCAD deacetylation, thereby improving nonalcoholic fatty liver disease in mice (66). Here, ACADL is linked to metabolic dysfunction-associated steatotic liver disease.